References
- AbramociczM2002Dutasteride (Avodart) for benign prostatic hyperplasiaMed Lett Drug Ther4410910
- ArrighiHMMetterEJGuessHA1991Natural history of benign prostatic hyperplasia and the risk of prostatectomy. The Baltimore Longitudinal Study of AgingUrology38Suppl. 1481714657
- BallAJFenelyRCLAbramsPH1981The natural history of untreated “prostatism”BJU Int5361316
- BostwickDGQianJCivantosF2004Does finasteride alter the pathology of the prostate and cancer grading?Clin Prostate Cancer22283515072606
- BramsonHNHermanDBatchelorKW1997Unique preclinical characteristics of GG745, a potent dual inhibitor of 5ARJ Pharmacol Exp Ther28214965029316864
- DesgrandchampsFDroupySIraniJ2006Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort in clinical practice. 2006BJU Int9883816831149
- GomellaLG2005Chemoprevention using dutasteride: The Reduce TrialCurr Opin Urol15293215586026
- JacobsenSJGirmanCJGuessHA1996Natural history of prostatism: Longitudinal changes in voiding symptoms in community dwelling menJ Urol1555956008558668
- LeporH1998Phase III multicenter placebo-controlled study of tamsulaosin in benign prostatic hyperplasia. Tamsulosin Investigator GroupUrol518929009609623
- McConnellJDRoehrbornCGBautistaOM2003The long-term effect of doxazocin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasiaN Engl J Med34924495114681512
- MerrickGSButlerWMWallnerKE2006Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapyUrol681162016844453
- O’LearyMPRoehrbornCAndrioleG2003Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitorBJU Int92262612887480
- [PDR] Thompson Micromedics2004Physicians desk referenceMontvale, NJThompson MicroMedex14569
- RoehrbornCGBoylePNickelJC2002Efficacy and safety of a dual inhibitor of 5α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasiaUrol604344112350480
- RoehrbornCMcConnellJBarryM2003AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendationsJ Urol1705304712853821
- RoehrbornCGSchwinnDA2004α1-Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasiaJ Urol17110293514767264
- RoehrbornCGLukkarinenOMarkS2005Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride: results of 4-year studiesBJU Int96572716104912
- SchulmanCPommervillePHofnerK2006Long-term therapy with dual 5α-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasiaBJU Int9773916336332
- ThompsonIMGoodmanPJTangenCM2003The influence of finasteride on the development of prostate cancerN Engl J Med3492152412824459